ClinicalTrials.gg
CompletedNCT03463876Updated Feb 17, 2026Results posted

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

A Phase 2 interventional study of SHR 1210+apatinib in Hepatocellular Carcinoma, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
190
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing camrelizumab in Carcinoma, Hepatocellular — 19 open to participants now, 24 under way, 8 of them phase 3. camrelizumab · Carcinoma, Hepatocellular.

Enrollment
10th of 44
190 · median 51
Started
2018
with 1 other
Phase 2
24 of 44
9 open now
Registered
3rd of 44
by date
Lead sponsor
5 of 44
Jiangsu HengRui Medicine Co., Ltd.

Among the 44 studies testing camrelizumab in Carcinoma, Hepatocellular, this one is the 10th largest by enrollment, is one of 2 that started in 2018, is one of 24 in phase 2, and was the 3rd registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

19 of the 44 studies testing camrelizumab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Where they have run

About camrelizumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing camrelizumab in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma.

Read the detailed description

SHR-1210 is a humanized monoclonal antibody against Programmed death 1(PD-1). Apatinib is a new kind of selective Vascular Endothelial Growth Factor Receptor 2(VEGFR-2) tyrosine kinase inhibitor (TKI).

Patients with advanced HCC who failed or intolerable to sorafenib will receive apatinib 250mg orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks. The efficacy and safety will be observed.

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18 years old, both genders.
  2. Conform to the clinical diagnosis standard strictly or histological or cytological confirmation of HCC(hepatocellular carcinoma) and with at least one by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to 1.1.
  3. Liver function status Class A.
  4. Barcelona Clinic Liver Cancer stage Category B or C.
  5. Failure or intolerance to prior treatment with targeted therapy.
  6. Performance Status of 0 or 1.
  7. of at least 12 weeks.
  8. Adequate bone marrow, liver and renal function (without blood transfusion, without growth factor or blood components support within 14 days before enrollment).

Exclusion criteria

Exclusion Criteria:

  1. Patients with any active disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded.
  2. Concurrent medical condition requiring the use of medications, or immunosuppressive doses of systemic or absorbable topical . Doses > 10 mg/day prednisone or equivalent are prohibited within 2 weeks before study drug administration.
  3. More than one regimen.
  4. Known history of to any components of the SHR-1210 formulation, or other antibody formulation.
  5. Known or occurrence of central nervous system (CNS) or hepatic encephalopathy.
  6. Patients with tumor burden ≥50% of the liver volume or received liver transplantation.
  7. Patients with clinical symptoms of ascites.
  8. Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents(within 3 months): systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg.
  9. cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, or coronary artery bypass surgery, Congestive heart failure ( (NYHA) class > 2), ventricular arrhythmia which need medical intervention.
  10. Coagulation abnormalities (>2.0、PT>16s), with bleeding tendency or are receiving thrombolytic or anticoagulant therapy.
  11. Previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency, such as: esophageal varices, local active ulcerative lesions, gastric ulcer and duodenal ulcer, the ulcerous colitis, gastrointestinal diseases such as portal hypertension or resection of tumor with bleeding risk, etc.
  12. Previous Arterial/venous thrombosis events within 3 months.
  13. Proteinuria ≥ (++) and 24 hours total urine protein > 1.0 g.
  14. Prior systemic chemotherapy, radiotherapy, immunotherapy, hormone therapy, surgery or target therapy within 4 weeks (Or 5 half-life of the drug, calculate the longer ) before the study drug administration, or any unresolved AEs > (CTCAE) Grade 1.
  15. Active infection or an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing.
  16. History of immunodeficiency or (HIV) infection.
  17. >2000 IU/ml(or 104copies/ml),>103copies/ml,HBsAg+ and anti-HCV+;
  18. Patients with other malignant tumor (except cured skin basal cell carcinoma and cervical carcinoma).
  19. Patients who has bone metastasis, has received Palliative radiotherapy (radiotherapy area > 5% marrow area).
  20. Patients must not have had prior treatment with SHR-1210 or any other or PD-1 antagonists or apatinib.
  21. Patients who may receive during the study, or previous had vaccination within 4 weeks.
  22. Any other medical, psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign , cooperate, and participate in the study or would interfere with the interpretation of the results.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    SHR-1210+Apatinib

    Patients will receive apatinib orally every day and SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks.

    Drug: SHR 1210+apatinib

Interventions

  • DrugSHR 1210+apatinib

    Drug pages: Camrelizumab · Apatinib

    SHR-1210 200mg (3mg/kg for underweight patients) iv every 2 weeks;Apatinib,250 mg/day.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

    Time frame: Up to approximately 12 months

Secondary outcomes

  1. Duration of Response (DoR)

    Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

    Time frame: Up to approximately 12 months

  2. Disease Control Rate (DCR)

    Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

    Time frame: Up to approximately 12 months

  3. Time to Objective Response(TTR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

    Time to objective response,TTR

    Time frame: Up to approximately 12 months

  4. 9-month Survival Rate

    9-month survival rate

    Time frame: Up to approximately 9 months

  5. 12-month Survival Rate

    12-month survival rate

    Time frame: Up to approximately 12 months

  6. Overall Survival(OS)

    Overall survival(OS)

    Time frame: Up to approximately 36 months

  7. Progression-free Survival(PFS)

    Progression-free survival(PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

    Time frame: Up to approximately 12 months

07

Results

Posted Feb 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneGroup Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic Treatment
Started12070
Completed168
Not completed10462

Outcome measures

PrimaryObjective Response Rate (ORR)

Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

Time frame:
Up to approximately 12 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR)
Percentage of participantsGroup Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic Treatment
Objective Response Rate (ORR)22.5 (15.4 to 31.0)34.3 (23.3 to 46.6)
SecondaryDuration of Response (DoR)

Duration of Response (DoR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

Time frame:
Up to approximately 12 months
Reported as:
Median · Months
Duration of Response (DoR)
MonthsGroup Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic Treatment
Duration of Response (DoR)NA (NA to NA)14.8 (5.5 to NA)
SecondaryDisease Control Rate (DCR)

Disease Control Rate (DCR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

Time frame:
Up to approximately 12 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsGroup Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic Treatment
Disease Control Rate (DCR)75.8 (67.2 to 83.2)78.6 (67.1 to 87.5)
SecondaryTime to Objective Response(TTR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

Time to objective response,TTR

Time frame:
Up to approximately 12 months
Reported as:
Median · Months
Time to Objective Response(TTR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
MonthsGroup Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic Treatment
Time to Objective Response(TTR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).1.87 (1.81 to 3.68)1.87 (1.84 to 3.70)
Secondary9-month Survival Rate

9-month survival rate

Time frame:
Up to approximately 9 months
Reported as:
Number · Percentage of participants
9-month Survival Rate
Percentage of participantsGroup Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic Treatment
9-month Survival Rate79.1 (70.7 to 85.4)86.7 (76.0 to 92.8)
Secondary12-month Survival Rate

12-month survival rate

Time frame:
Up to approximately 12 months
Reported as:
Number · Percentage of participants
12-month Survival Rate
Percentage of participantsGroup Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic Treatment
12-month Survival Rate68.2 (59.0 to 75.7)74.7 (62.5 to 83.5)
SecondaryOverall Survival(OS)

Overall survival(OS)

Time frame:
Up to approximately 36 months
Reported as:
Median · Months
Overall Survival(OS)
MonthsGroup Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic Treatment
Overall Survival(OS)21.8 (17.3 to 25.6)20.1 (14.9 to NA)
SecondaryProgression-free Survival(PFS)

Progression-free survival(PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).

Time frame:
Up to approximately 12 months
Reported as:
Median · Months
Progression-free Survival(PFS)
MonthsGroup Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic Treatment
Progression-free Survival(PFS)5.5 (3.7 to 5.6)5.7 (5.4 to 7.4)

Adverse events

Collected over 36 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SHR 1210+Apatinib118/190 (62.1%)92/190 (48.4%)189/190 (99.5%)
Most frequent serious events
Showing 10 of 78
Most frequent serious events
EventSHR 1210+Apatinib
Hepatic enzyme abnormalInvestigations15/190
Disease progressionGeneral disorders13/190
Hepatic function abnormalHepatobiliary disorders7/190
PyrexiaGeneral disorders5/190
Multiple organ dysfunction syndromeGeneral disorders4/190
PneumoniaInfections and infestations4/190
PneumonitisRespiratory, thoracic and mediastinal disorders4/190
Reactive capillary endothelial proliferationImmune system disorders4/190
Sudden cardiac deathGeneral disorders3/190
Alanine aminotransferase increasedInvestigations3/190
Most frequent other events
Showing 10 of 79
Most frequent other events
EventSHR 1210+Apatinib
Aspartate aminotransferase increasedInvestigations138/190
Platelet count decreasedInvestigations125/190
Alanine aminotransferase increasedInvestigations116/190
ProteinuriaRenal and urinary disorders112/190
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders108/190
White blood cell count decreasedInvestigations107/190
Blood bilirubin increasedInvestigations98/190
HypertensionVascular disorders95/190
Neutrophil count decreasedInvestigations89/190
AstheniaGeneral disorders76/190

Baseline characteristics

Age, Continuous
Age, Continuous(years)Group Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic TreatmentTotal
Mean50.7 ± 1151.9 ± 11.2851.1 ± 11.09
Sex: Female, Male
Sex: Female, Male(Participants)Group Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic TreatmentTotal
Female14721
Male10663169
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Group Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic TreatmentTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Group Having Received First-Line Systemic TreatmentGroup Not Having Received First-Line Systemic TreatmentTotal
China12070190
08

Study locations

1 site
  • The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
    Beijing, Beijing Municipality 100071, China
09

References and documents

Publications

  • Zhou X, Cao J, Topatana W, Xie T, Chen T, Hu J, Li S, Juengpanic S, Lu Z, Zhang B, Wang K, Feng X, Shen J, Chen M. Evaluation of PD-L1 as a biomarker for immunotherapy for hepatocellular carcinoma: systematic review and meta-analysis. Immunotherapy. 2023 Apr;15(5):353-365. doi: 10.2217/imt-2022-0168. Epub 2023 Feb 27. PubMed 36852452 ↗
  • Xu J, Shen J, Gu S, Zhang Y, Wu L, Wu J, Shao G, Zhang Y, Xu L, Yin T, Liu J, Ren Z, Xiong J, Mao X, Zhang L, Yang J, Li L, Chen X, Wang Z, Gu K, Chen X, Pan Z, Ma K, Zhou X, Yu Z, Li E, Yin G, Zhang X, Wang S, Wang Q. Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. Clin Cancer Res. 2021 Feb 15;27(4):1003-1011. doi: 10.1158/1078-0432.CCR-20-2571. Epub 2020 Oct 21. PubMed 33087333 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Mar 2021, 36 months.

Results were first posted in Feb 2026, 4 years 11 months after primary completion.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 36 months is close to that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2018
First posted
Mar 13, 2018
StartActual
Mar 8, 2018
Primary completionActual
Mar 10, 2021
CompletionActual
Mar 10, 2021
Results first posted
Feb 17, 2026
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03463876
Responsible party
Sponsor
First posted
Mar 13, 2018
Start date
Mar 8, 2018
Primary completion
Mar 10, 2021
Completion
Mar 10, 2021
Results posted
Feb 17, 2026
Last update
Feb 17, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Camrelizumab · Apatinib

Start the discussion